Adagene (NASDAQ:ADAG – Get Free Report) and CytomX Therapeutics (NASDAQ:CTMX – Get Free Report) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, dividends, risk, earnings and valuation.
Profitability
This table compares Adagene and CytomX Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Adagene | N/A | N/A | N/A |
| CytomX Therapeutics | -22.79% | -19.77% | -11.91% |
Analyst Ratings
This is a summary of recent recommendations and price targets for Adagene and CytomX Therapeutics, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Adagene | 1 | 0 | 2 | 2 | 3.00 |
| CytomX Therapeutics | 1 | 0 | 9 | 0 | 2.80 |
Earnings and Valuation
This table compares Adagene and CytomX Therapeutics”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Adagene | $7.67 million | 24.52 | -$33.42 million | N/A | N/A |
| CytomX Therapeutics | $76.20 million | 10.18 | -$17.37 million | ($0.04) | -114.00 |
CytomX Therapeutics has higher revenue and earnings than Adagene.
Institutional & Insider Ownership
9.5% of Adagene shares are owned by institutional investors. Comparatively, 67.8% of CytomX Therapeutics shares are owned by institutional investors. 21.2% of Adagene shares are owned by company insiders. Comparatively, 6.6% of CytomX Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Risk & Volatility
Adagene has a beta of 0.58, suggesting that its stock price is 42% less volatile than the S&P 500. Comparatively, CytomX Therapeutics has a beta of 2.49, suggesting that its stock price is 149% more volatile than the S&P 500.
Summary
Adagene beats CytomX Therapeutics on 7 of the 13 factors compared between the two stocks.
About Adagene
Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company's product candidates include ADG106, a human ligand-blocking agonistic anti- CD137 IgG4 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a masked fully-human anti-CTLA-4 mAb that is in Phase 1 clinical trial for the treatment advanced/metastatic solid tumors; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase 1b/2 clinical development for the treatment of advanced/metastatic solid tumors. It also offers ADG104, an anti-PD-L1 mAb that is in Phase 2 clinical development; ADG125, a novel anti-CSF-1R mAb, which is in Phase I clinical trial; ADG206, a masked, Fc engineered anti-CD137 agonistic POWERbody; ADG153, a masked anti-CD47 IgG1 SAFEbody, which is in preclinical for the treatment hematologic and solid tumors; ADG138, novel HER2xCD3 POWERbody, which is in preclinical for the treatment HER2-expressing solid tumors; and ADG152, a v POWERbody, which is in preclinical stage for the treatment off-tumor toxicities, as well as develops anti-CD28 bispecific POWERbody TCEs. The company was incorporated in 2011 and is headquartered in Suzhou, China.
About CytomX Therapeutics
CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.
Receive News & Ratings for Adagene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adagene and related companies with MarketBeat.com's FREE daily email newsletter.
